[at Barrons.com] – Credit Suisse likes Celgene (CELG). It really likes Celgene. Credit Suisse analyst Ravi Mehrotra and team raised Celgene to Outperform from Neutral, putting it on par with Outperform rated Biogen Idec (BIIB) and Gilead (GILD) and a notch above Neutral-rated Amgen (AMGN). What’s to like? Let Credit Suisse analysts explain: We are raising 2017 total sales and EPS to $13B (from $11B, consensus and guidance $12B/at least $12B) and $16.00 (from $13.57, consensus … [visit site to read more]
- Celgene Corporation (NASDAQ:CELG) ~ Celgene Upgraded By Credit Suisse, Market Shrugs; More Biotech Upside Ahead?
- Stock market seasonality mid-year update
- Credit Card Stocks: The Credit Card Fair Fee Act may kill the interchange fee… and credit card company revenues
